Journal of Clinical & Experimental Pharmacology

Assessing the possibilities and risks associated with aurora kinase a targeting drug in breast cancer

36^th World Congress on Pharmacology

July 25, 2023 | Webinar

Debomita Sengupta

Chittaranjan National Cancer Institute (CNCI), India

Keynote: J Clin Exp Pharmacol

Abstract:

Given the overexpression of Aurora Kinase A (AURKA) in 94% of breast cancer cases, AURKA-inhibitors have been tested without any betterment in response compared to conventional chemotherapeutic regimen proving that AURKA expression is dispensable during dissemination of breast cancer stem cells (BCSCs). In our study, we have observed AURKA upregulation by Oct4/Sox2 indicating that BCSCs may be targeted through AURKA in the cells undergoing active cell-cycle. However, the quiescent BCSCs without AURKA expression were found to circulate in patient blood irrespective of chemotherapeutic regimen demonstrating lack of the proliferative phase as an escaping route against chemotherapeutic regimen or AURKA-targeted therapies.

Biography :

Debomita Sengupta has been working on breast cancer signaling pathways, diagnostics and treatment aspects for 15 years. Apart from her contributions in the reputed international journals in form of articles, reviews and book chapters, she has been a recipient of multiple prestigious research fellowships from the University Grants Commission, Department of Science and Technology and the Council of Scientific and Industrial Research, Govt. of India. Her PhD work was selected for presentation in the late-breaking category of the Annual Meeting of AACR; her postdoctoral work was selected for presentation in ESMO and honorary flash talk in Society of Biological Chemists, Kolkata. In addition to her work at CNCI, she is currently a member reviewer of the international journals like the Cellular Oncology, BMC Bioinformatics, Journal of Ovarian Research, Current Pharmacology Reports and American Journal of Translational Medicine.